Allergan plc, a leading global biopharmaceutical company, today announced that Daphne Karydas will take on the new role of Senior Vice President Corporate Financial Planning & Analysis and Strategy, and Manisha Narasimhan, PhD, will join the Company as Vice President of Investor Relations and Strategic Initiatives, effective December 10, 2018.
In her new role, Ms. Karydas will continue to work with the Executive Leadership Team to develop and execute the Company’s long-term financial and business strategy. Dr. Narasimhan, who joins Allergan from Regeneron Pharmaceuticals, Inc., will lead the Company’s engagement with the investment community. Both roles will report to Matt Walsh, Executive Vice President and Chief Financial Officer.
“The changes we are announcing today will enable us to further deepen our focus on the corporate strategic and financial planning functions to realize Allergan’s long-term growth potential, while continuing to develop and steward the strong relationships we have established across the financial community,” said Walsh.
Dr. Narasimhan joins Allergan from Regeneron, where she led the Investor Relations function. She has extensive industry experience in the biopharmaceutical sector and well-established relationships within the investment community. Previously, she was an equity research analyst at Canaccord Genuity and Piper Jaffray and has also served as a strategy consultant at Campbell Alliance. Dr. Narasimhan holds a B.Sc. from University of Madras in India and a PhD in Microbiology from New York University.
“We always look to position ourselves to deliver the highest value to patients, customers and shareholders,” said Brent Saunders, Chairman and Chief Executive Officer of Allergan. “A strong financial and strategic planning capability is essential to Allergan’s growth, and Daphne’s leadership in this area will help take us to the next level. With Manisha’s impressive mix of financial and biopharma industry experience, we will continue to build on the solid foundation Daphne set in Investor Relations.”
Ms. Karydas recently served as Senior Vice President Global Investor Relations and Strategy. Before that time, she was a leading institutional investor and financial analyst in the biopharmaceutical sector, joining from J.P. Morgan Asset Management. Ms. Karydas holds a B.A. and M.S. in chemical engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.
Source: Allergan via MarketWatch
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.